Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

It's shaping up to be a tough period for Bonesupport Holding AB (publ) (STO:BONEX), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock. It wasn't a great result overall - while revenue fell marginally short of analyst estimates at kr294m, statutory earnings missed forecasts by an incredible 32%, coming in at just kr0.52 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the consensus forecast from Bonesupport Holding's five analysts is for revenues of kr1.61b in 2026. This reflects a huge 44% improvement in revenue compared to the last 12 months. Per-share earnings are expected to leap 136% to kr5.45. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr1.68b and earnings per share (EPS) of kr5.78 in 2026. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the small dip in earnings per share expectations.

View our latest analysis for Bonesupport Holding

Despite the cuts to forecast earnings, there was no real change to the kr395 price target, showing that the analysts don't think the changes have a meaningful impact on its intrinsic value. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Bonesupport Holding analyst has a price target of kr471 per share, while the most pessimistic values it at kr340. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Bonesupport Holding'shistorical trends, as the 34% annualised revenue growth to the end of 2026 is roughly in line with the 40% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 15% annually. So although Bonesupport Holding is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Bonesupport Holding. They also downgraded Bonesupport Holding's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. The consensus price target held steady at kr395, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Bonesupport Holding going out to 2027, and you can see them free on our platform here.

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Bonesupport Holding that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.